{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:37:14Z","timestamp":1788385034580,"version":"build-2803163510"},"reference-count":37,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2005,4,13]],"date-time":"2005-04-13T00:00:00Z","timestamp":1113350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2005,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The objectives of the current study were to evaluate the outcome of patients \u2265 60 years with acute myeloid leukemia (AML) treated uniformly with high\u2010dose daunorubicin containing induction and modified high\u2010dose cytosine arabinoside containing postremission therapy, and to identify factors predictive of complete disease remission (CR) and survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Between 1998 and 2002, the authors treated 117 newly diagnosed patients (acute promyelocytic leukemia excluded) with AML \u2265 60 years (median, 67 years; range, 60\u201382 years). Karyotype (Medical Research Council classification) at diagnosis was categorized as good risk (<jats:italic>n<\/jats:italic> = 3), intermediate risk (<jats:italic>n<\/jats:italic> = 69), adverse risk (<jats:italic>n<\/jats:italic> = 26), and suboptimal\/not done (<jats:italic>n<\/jats:italic> = 19). A normal karyotype was seen in 41 patients and 40 (34%) had secondary AML.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The outcome of induction included the following: CR, 62 (53%); early death, 5 (4%); death during hypoplasia, 14 (12%); and resistant disease, 36 (31%). The 3\u2010year event\u2010free (EFS) and overall survival (OS) rates were 9% (95% confidence interval [95% CI], 3\u201316%) and 17% (95% CI, 9\u201329%), respectively. In a univariate analysis, cytogenetics, lactate dehydrogenase level, leukocyte count, and performance status were the significant factors for EFS and OS. Age was not a significant prognostic factor for either CR or survival. In a multivariate model, adverse\u2010risk cytogenetics, previous history of myelodysplastic syndrome or antecedent hematologic disorder, and high leukocyte count (&gt; 30 \u00d7 10<jats:sup>9<\/jats:sup>\/L) were independent adverse prognostic factors for survival. The impact of adverse karyotype on EFS and OS was time dependent and was observed after 50 and 150 days, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The authors concluded that candidacy for intensive therapy in older patients should be based on biologic features of disease and fitness, rather than on age. Cancer 2005. \u00a9 2005 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21006","type":"journal-article","created":{"date-parts":[[2005,4,13]],"date-time":"2005-04-13T18:47:51Z","timestamp":1113418071000},"page":"2082-2090","source":"Crossref","is-referenced-by-count":79,"title":["Disease biology rather than age is the most important determinant of survival of patients \u2265 60 years with acute myeloid leukemia treated with uniform intensive therapy"],"prefix":"10.1002","volume":"103","author":[{"given":"Vikas","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi\u2010Long","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Minden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Brandwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,4,13]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.9.3323"},{"key":"e_1_2_5_3_2","first-page":"2952","article-title":"Use of recombinant GM\u2010CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML\u201011, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato\u2010Oncology Cooperative Group","volume":"90","author":"Lowenberg B","year":"1997","journal-title":"Blood."},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1312"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03043.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0354"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1686"},{"key":"e_1_2_5_8_2","first-page":"2722","article-title":"A placebo\u2010controlled study of recombinant human granulocyte\u2010macrophage colony\u2010stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients","volume":"91","author":"Witz F","year":"1998","journal-title":"Blood."},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.10.3607"},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1200\/JCO.1998.16.3.872","article-title":"Mitoxantrone versus daunorubicin in induction\u2010consolidation chemotherapy\u2014the value of low\u2010dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report","volume":"16","author":"Lowenberg B","year":"1998","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1302"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.3.548"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.4.1224.h81602001224_1224_1232"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb03256.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.00398.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12<2476::AID-CNCR10>3.0.CO;2-P"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02981978"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200188"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0650-0"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1686"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912303412706"},{"key":"e_1_2_5_22_2","first-page":"786","article-title":"Results of chemotherapy for unselected patients with acute myeloblastic leukaemia: effect of exclusions on interpretation of results","volume":"1","author":"The Toronto Leukemia Study Group","year":"1986","journal-title":"Lancet."},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1991.tb00547.x"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.186"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410063311402"},{"key":"e_1_2_5_26_2","volume-title":"An international system for human cytogenetic nomenclature","author":"Mitelman F","year":"1995"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950040311"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009612305785"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.7.2322"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.9.1268"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506223322503"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3569"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02511.x"},{"key":"e_1_2_5_35_2","first-page":"231","article-title":"De novo acute myeloid leukaemia in patients over 55\u2010years\u2010old: a population\u2010based study of incidence, treatment and outcome","volume":"9","author":"Taylor PR","year":"1995","journal-title":"Leukemia."},{"key":"e_1_2_5_36_2","doi-asserted-by":"crossref","first-page":"249a","DOI":"10.1182\/blood.V104.11.872.872","article-title":"Low dose ara\u2010C versus hydroxyurea with or without retinoid in older patients not considered fit for intensive chemotherapy","volume":"104","author":"Burnett A","year":"2004","journal-title":"Blood."},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.1123"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1537"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21006","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:38:50Z","timestamp":1760290730000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,13]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,5,15]]}},"alternative-id":["10.1002\/cncr.21006"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21006","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,13]]}}}